Phosphodiesterase Inhibitors Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global phosphordiesterase inhibitors market is anticipated to grow at a CAGR of 4.3% during the forecast period (2022-2028). A phosphodiesterase inhibitor is defined as a drug that hinders one or more of the five subtypes of the enzyme phosphodiesterase. This, in turn, is preventing the inactivation of the intracellular second messengers, cyclic adenosine monophosphate and cyclic guanosine monophosphate by the respective phosphodiesterase subtype. Furthermore, the novel usage of these drugs in treating several diseases is driving the market growth during the forecast period. Majorly the two types of phosphodiesterase inhibitors including the selective and non-selective are being discovered as possible treatments for various indications, such as chronic obstructive pulmonary disease (COPD), Alzheimer’s disease, and other ailments. Cytosol, plasma membranes, nuclear membranes, endoplasmic reticulum, and cytoskeleton have these inhibitors.

R&D and novel launches too have substantially contributed to the global phosphodiesterase inhibitors market. For instance, in July 2018, Adamis Pharmaceuticals Corp. (Adamis) announced that it has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil, which is a drug used to treat erectile dysfunction. Further, in September 2020, Aspargo Laboratories, Inc. acquired the international rights to Sildenafil oral spray for the treatment of erectile dysfunction. Another pivotal factor that is driving the global PDE inhibitors market growth include the rise in the prevalence of erectile dysfunction disorder. According to the World Health Organization, about 150 million people have been affected by erectile dysfunction across the global and the number is projected to reach 230 million by 2025. It is a common medical condition affecting about 15% of men each year.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-

• By Type
• By Application

• Regions covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape: Bayer AG, Eli Lilly and Co., and GlaxoSmithKline plc, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

• Deviation from the pre-COVID-19 forecast
• Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Phosphodisterase Inhibitors Market Report by Segment

By Type

• PDE1 Selective Inhibitors
• PDE2 Selective Inhibitors
• PDE3 Selective Inhibitors
• PDE4 Selective Inhibitors
• PDE5 Selective Inhibitors
• PDE7 Selective Inhibitors
• PDE10 Selective Inhibitors

By Application

• Oral
• Topical
• Others